Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Introgen Therapeutics Inc: Premium Company Profile

Published by: Datamonitor

Published: Apr. 22, 2008 - 53 Pages


Table of Contents


Overview
Catalyst
Summary
Table of Contents
Table of figures
Table of tables
Company Structure
Company Overview and Key Facts
Business Description
Landmark Products and Services
Enabling Technologies
History
M&A History
Magnum Therapeutics
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
In-house Pipeline
Advexin
INGN 241
INGN 225
INGN 401
INGN 234
INGN 402
INGN 403
INGN 007
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Broad proprietary pipeline
Strong intellectual property
Weaknesses
Contract Manufacturing Services
Opportunities
Advexin therapy
Anti-cancer drug market
Threats
Regulatory impact on nature of business
Conflicting obligations
Value Chain Analysis
Overview
Discovery and Product Development
Manufacturing
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
David G Nance
William H Cunningham
S Malcolm Gillis
Peter Barton Hutt
John N Kapoor
Charles E Long
James W Albrecht
C Channing Burke
Max W Talbott
Robert E Sobol
J David Enloe
Kerstin B Menander
David L Parker
Sunil Chada
Financial and Operational Overview
Financial and Operational Overview
APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer
List of Tables
Table 1: Introgen - Key Facts
Table 2: Introgen - Other Locations and Subsidiaries
Table 3: Introgen - Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: Introgen - Key Events Impacting Share Price Performance
Table 5: Introgen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: Introgen - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: Introgen - Balance Sheet, 2002-2006 ($ Mn)
Table 8: Introgen - Cash Flow, 2002-2006 ($ Mn)
Table 9: Introgen - In-house Pipeline Products
Table 10: Introgen - Forecast Sales, 2006-2010 ($ Mn)
Table 11: Introgen - Key Competitors
Table 12: Introgen - Key Suppliers
Table 13: Introgen - Key Clients
Table 14: Introgen - Key Shareholders
Table 15: Introgen - SWOT Analysis Summary
Table 16: Introgen - Value Chain Analysis
Table 17: Introgen - Scorecard
Table 18: Introgen - Key Employees
Table 19: Introgen - Financial and Operational Overview
List of Figures
Figure 1: Introgen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Introgen - Key Strategic Revenues, 2006-2010 ($ Mn)


Abstract

Introduction

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of pipeline candidates using its ‘Enabling Technologies’.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company’s product candidates include includes five clinical-stage product candidates: ADVEXIN and INGN 241 in Phase III clinical trials for head and neck cancer; INGN 225, a therapeutic p53 vaccine, in Phase II clinical development for lung and breast cancer. The company's INGN 234, a topical formulation for oral cancer prevention and treatment of oral pre-malignancies, in Phase I clinical development; and INGN 401, a systemic nanoparticle tumor suppressor is in Phase II clinical trials for metastatic lung cancer. The company recognizes revenues in the form of contract research fees from other pharmaceutical/biotechnology companies, and grants from academic and government organizations. The company’s total revenues have slightly declined at a CAGR of 0.5% during 2002-2006, almost flat at $1.2 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .

Please note: This is delivered as a Zip file.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008